UK's NHS demands new standard to fight antimicrobial resistance

14 August 2024

Pharmaceutical companies supplying products under the UK’s freshly-launched antibiotics subscription model must now certify compliance with a new industry standard.

The “BSI Kitemark for Minimized Risk of Antimicrobial Resistance (AMR)” aims to ensure responsible antibiotic manufacturing and reduce the environmental impact that contributes to the growing AMR crisis.

The move aligns with the 2024-2029 UK National AMR Action Plan, which emphasizes stringent controls on antibiotic production.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical